CD69 and adenocarcinoma: Thus, the analysis of the cellular parameters (Tregs, intermediate monocytes), plasma proteins (CD25 on CD3+ T-cells, FAS-L, ICOS-L, CEACAM1/CD66a, CD207, CYR61, MADH5, MIC-A/B), and functional assays (in vitro stimulation of CD69-expression and cytokine release) did not provide evidence for persistent alterations of the immune status in adenocarcinoma patients (Fig. 5, Additional file 1: Table S1).